Works matching IS 22351795 AND DT 2024 AND VI 13 AND IP 4

Results: 11
    1

    Front & Back Matter.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 1, doi. 10.1159/000540810
    Publication type:
    Article
    2
    3

    A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 438, doi. 10.1159/000536518
    By:
    • Huang, Zhi-Mei;
    • Han, Xue;
    • Wang, Jian;
    • Gu, Ling;
    • Tang, Lu;
    • Wu, Shao-Yong;
    • Di, Tian;
    • Hou, Ying-Wen;
    • Lau, Wan Yee;
    • Jiang, Yi-Quan;
    • Huang, Jin-Hua
    Publication type:
    Article
    4
    5

    Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 413, doi. 10.1159/000535839
    By:
    • Nam, Heechul;
    • Lee, Jaejun;
    • Han, Ji Won;
    • Lee, Soon Kyu;
    • Yang, Hyun;
    • Lee, Hae Lim;
    • Sung, Pil Soo;
    • Kim, Hee Yeon;
    • Kim, Seok-Hwan;
    • Song, Myeong Jun;
    • Kwon, Jung-Hyun;
    • Kim, Chang Wook;
    • Nam, Soon Woo;
    • Bae, Si Hyun;
    • Choi, Jong Young;
    • Yoon, Seung Kew;
    • Jang, Jeong Won
    Publication type:
    Article
    6

    Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 401, doi. 10.1159/000535501
    By:
    • Kudo, Masatoshi;
    • Tsuchiya, Kaoru;
    • Shao, Yu-Yun;
    • Finn, Richard S.;
    • Galle, Peter R.;
    • Ducreux, Michel;
    • Cheng, Ann-Lii;
    • Yamashita, Tatsuya;
    • Koga, Hironori;
    • Take, Ryosuke;
    • Yamada, Kyoko;
    • Asakawa, Takashi;
    • Nakagawa, Yuki;
    • Ikeda, Masafumi
    Publication type:
    Article
    7
    8
    9

    A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 451, doi. 10.1159/000535154
    By:
    • Kudo, Masatoshi;
    • Finn, Richard S.;
    • Ikeda, Masafumi;
    • Sung, Max W.;
    • Baron, Ari D.;
    • Okusaka, Takuji;
    • Kobayashi, Masahiro;
    • Kumada, Hiromitsu;
    • Kaneko, Shuichi;
    • Pracht, Marc;
    • Meyer, Tim;
    • Nagao, Satoshi;
    • Saito, Kenichi;
    • Mody, Kalgi;
    • Ramji, Zahra;
    • Dubrovsky, Leonid;
    • Llovet, Josep M.
    Publication type:
    Article
    10
    11

    A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 389, doi. 10.1159/000535338
    By:
    • Qin, Shukui;
    • Fang, Weijia;
    • Ren, Zhenggang;
    • Ou, Shuangyan;
    • Lim, Ho Yeong;
    • Zhang, Feng;
    • Lee, Kin Chung;
    • Choi, Hye Jin;
    • Tong, Jiandong;
    • Tao, Min;
    • Xu, Aibing;
    • Cheng, Ashley;
    • Lu, Chang-Hsien;
    • Chiu, Chang-Fang;
    • Wahid, Mohamed Ibrahim Abdul;
    • Kamble, Shital;
    • Norquist, Josephine M.;
    • Zhong, Wenyan;
    • Li, Chen;
    • Chen, Zhendong
    Publication type:
    Article